A blood test may tailor breast cancer treatment for older women
medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …
AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.
- EBCC15: Less overtreatment through personalized radiotherapy and surveillance (4)
- Liquid biopsies and sensors advancing cancer detection beyond breast (4)
- Other: biology and global burden stories (3)
- Ultrasensitive ctDNA: tailoring breast cancer care for older patients (5)
- All Other Stories
EBCC15: Less overtreatment through personalized radiotherapy and surveillance
Liquid biopsies and sensors advancing cancer detection beyond breast
Other: biology and global burden stories
Ultrasensitive ctDNA: tailoring breast cancer care for older patients
All Other Stories
Vivek Subbiah: New Nature Study on Thymic Health and Response
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]
AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.
- Aging immunity: why older immune systems fail us (5)
- Front lines: new targets and tactics in cancer immunotherapy (9)
- On the ground: adult thymus drives longevity and therapy success (5)
- All Other Stories
Aging immunity: why older immune systems fail us
Front lines: new targets and tactics in cancer immunotherapy
On the ground: adult thymus drives longevity and therapy success
All Other Stories
TerraPower Isotopes Invests $450M in Actinium-225 Production Facility
oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…
AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.
Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Elizabeth Cairns / endpoints - Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study. The triple-G ...
AI Summary: Eli Lilly’s third‑generation GLP‑1 candidate reported Phase 3 data demonstrating significant weight loss and A1C reductions, with efficacy appearing comparable to existing therapies like Mounjaro. The results sharpen competition in the GLP‑1 market and raise questions about pricing, access and who gets first dibs on the next blockbuster injection.
- At clinics: GLP‑1 demand reshaping access, care and pricing (5)
- In labs: oral pills and novel GLP‑1 delivery approaches (4)
- On the ground: Lilly's triple‑G rivaling Mounjaro in trials (3)
- Other: clinical oddities, surgical implications and pipeline setbacks (5)
At clinics: GLP‑1 demand reshaping access, care and pricing
In labs: oral pills and novel GLP‑1 delivery approaches
On the ground: Lilly's triple‑G rivaling Mounjaro in trials
Other: clinical oddities, surgical implications and pipeline setbacks
A liquid biopsy blood test may improve children's survival of cancer in Africa
medicalxpress - In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam, Tanzania have shown that a minimally invasive liquid biopsy test can diagnose Burkitt l…
AI Summary: A blood‑based liquid biopsy for EBV‑positive Burkitt’s lymphoma shows promise for earlier, less invasive diagnosis in endemic regions, potentially improving pediatric survival where tissue biopsies are scarce. Early data indicate actionable sensitivity and feasibility for low‑resource settings, offering a scalable path to faster treatment.
Engineered tissue offers hope for children born with 'missing' esophagus
medicalxpress - Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown esophagus—the food pipe—shown to safely replace a full section of the organ and restore normal function, including swallowing, in a gr…
AI Summary: Researchers report progress developing lab-grown esophageal tissue to treat children born with congenital absence or severe damage of the esophagus. Early preclinical and surgical work demonstrates that engineered tissue constructs can be implanted and integrated, offering a potential alternative to complex reconstructions — a promising step for tiny patients with very big problems.